
Genetic Therapy Inc (AKA: GTI) Profile last edited on: 6/2/21
CAGE:
UEI:
Business Identifier: Therapies based on insertion of gene-modified cells into patient's body Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
938 Clopper Road
Gaithersburg, MD 20878
Gaithersburg, MD 20878
(301) 590-2626 |
N/A |
N/A |
Location: Single
Congr. District: 06
County: Montgomery
Congr. District: 06
County: Montgomery
Public Profile
In December 1995, Genetic Therapy Inc (NASDAQ:GTII) was acquired by Sandoz Ltd (merged with Ciba-Geigt Ltd to become Novartis) - a firm with which there had been a long standing working relationship. GTI is an indirect wholly owned subsidiary of Novartis and is now established as the Novartis Center of Excellence for gene therapy. Organized fromtheoutset around bringing to market gene therapy products for the treatment of life-threatening genetic and acquired diseases, Genetic Therapy's novel approach involved insertion of genes into cells to produce therapeutic proteins in the body, or the genetic vectors themselves can destroy cells that are malignant (oncolytic vectors). A pioneer in gene delivery technologies, GTI is focused on developing breakthrough solutions for the healthcare area considered most promising to gene therapy -- cancer. GTI holds a leading position in oncolytic vectors, viruses that selectively kills cancer cells, offering the prospect of effectively treating a wide range of cancers at increased safety and lower toxicity to patients. Complementing the emphasis on oncolytic vectors, GTI is also exploring gene therapies that attack tumors by inhibiting their blood supply, also known as anti-angiogenesis.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
500+Revenue Range
Over 50MVC funded?
YesPublic/Private
Publicly TradedStock Info
NASDAQ : GTIIIP Holdings
15-19Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
1995 | 1 | NIH | $97,730 | |
Project Title: Targeting Adeno Vectors by Fiber Protein Engineering | ||||
1995 | 1 | NIH | $99,982 | |
Project Title: Upregulaton of HSV TK Gene & Brain Cancer Gene Therapy | ||||
1994 | 2 | NIH | $550,000 | |
Project Title: Retroviral vectors to express Alpha-IFN in human TIL | ||||
1993 | 2 | NIH | $549,791 | |
Project Title: Generation and study of IL-1 secreting TIL cells | ||||
1990 | 1 | NIH | $48,760 | |
Project Title: Liver growth factor gene cloning and expression |
Key People / Management
Mike Perry -- President
Yung-Nien Chang
Yawen L Chiang
Alan McClelland
Robert C Moen
Paul Tolstoshev
Yung-Nien Chang
Yawen L Chiang
Alan McClelland
Robert C Moen
Paul Tolstoshev
Company News
There are no news available.